angiotensin 1-7 Report issue

Biologics Peptide Experimental
AACT ChEMBL DrugBank Drug Central MeSH PubChem

Active Ingredient History

NOW
  • Now
Angiotensinamide is octapeptide amide of bovine angiotensin II used to increase blood pressure by vasoconstriction. Angiotensinamide is indicated for the treatment of severe hypotension unresponsive to traditional pressor agents. Angiotensinamide has a strong pressure effect, due to the increased peripheral resistance of blood vessels, especially small caliber arterioles. Under the influence of angiotensinamide, the vessels of the internal organs, skin, kidneys are particularly narrowed. Blood circulation in skeletal muscles and coronary vessels does not change significantly. The drug has no direct effect on the heart and does not cause arrhythmias in therapeutic doses. Angiotensinamide is rapidly inactivated by enzymes contained in the blood, and therefore, when administered once, it has a short-term (2–3 min) pressure effect. However, the duration of the effect can be relatively easily controlled by selecting the appropriate rate of administration of the drug solution.   NCATS

Chemistry

  • SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N3CCC[C@H]3C(=O)O
  • InChIKey: PVHLMTREZMEJCG-GDTLVBQBSA-N
  • Mol. Mass: 899.02
  • ALogP: -1.83
  • ChEMBL Molecule:
    txa127  
More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

ang i (1-7) | angiotensin (1-7) | angiotensin 1-7 | angiotensin-(1-7) | angiotensinamide | angiotensin i (1-7) | angiotensin-i (1-7) | angiotensin ii (1-7) | angiotensin ii-(1-7) | angiotensin ii (1-7) heptapeptide | txa127 | txa-127

Organizations (27)

Research & Development (27)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (45)

Approved Indications (1)


 

Shock

Experimental Indications - Clinical Trial Phases 1-4 (44)


 

Anemia (Phase 2)

Autonomic Nervous System Diseases (Early Phase 1)

Blood (Phase 1)

Bone Neoplasms (Phase 2)

Chondrosarcoma (Phase 2)

Cognitive Dysfunction (Phase 2)

Cord Blood Stem Cell Transplantation (Phase 2)

Coronary Artery Bypass (Phase 2)

Coronavirus (Phase 2/Phase 3)

Coronavirus Infections (Phase 2/Phase 3)

COVID-19 (Phase 2/Phase 3)

Essential Hypertension (Phase 1)

Hematologic Neoplasms (Phase 2)

HIV Infections (Phase 1)

Hodgkin Disease (Phase 2)

Hypertension (Phase 1)

Insulin Resistance (Phase 1)

Kidney Diseases (Phase 2)

Leiomyosarcoma (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Lymphoma, Non-Hodgkin (Phase 2)

Lymphopenia (Phase 2)

Metabolic Diseases (Phase 2)

Metabolic Syndrome (Phase 1)

Multiple Myeloma (Phase 2)

Myelodysplastic Syndromes (Phase 1)

Neoplasms (Phase 1)

Neutropenia (Phase 2)

Obesity (Phase 1)

Osteosarcoma (Phase 2)

Ovarian Neoplasms (Phase 2)

Peripheral Arterial Disease (Early Phase 1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Primary Myelofibrosis (Phase 1)

Pure Autonomic Failure (Early Phase 1)

Respiratory Distress Syndrome (Phase 2)

Respiratory Insufficiency (Phase 2/Phase 3)

Sarcoma (Phase 2)

SARS-CoV-2 (Phase 2/Phase 3)

Severe Acute Respiratory Syndrome (Phase 3)

Shy-Drager Syndrome (Early Phase 1)

Thrombocytopenia (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 30
  • # of Trial Organizations: 27

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue